NASDAQ:PRAX News 16 October 2025

Praxis Precision Medicines (PRAX) Soars on FDA Momentum and 760-Dollar Target: December 9, 2025 Stock Deep Dive

Praxis Precision Medicines, Inc. (NASDAQ: PRAX) has turned into one of 2025’s most dramatic biotech stories. On December 9, 2025, the stock is trading around $265–270 per share, near its 52‑week high of about $278 and far above its low

9 December 2025

Praxis Precision Medicines (PRAX) Stock Soars After Epilepsy Breakthrough and FDA Pre‑NDA Win

Praxis Precision Medicines, Inc. (NASDAQ: PRAX) ripped higher again on 5 December 2025, extending one of the most dramatic biotech rallies of the year after positive epilepsy data and a favorable pre‑NDA meeting with the FDA. By the closing bell

6 December 2025

Biotech News · FDA Approvals · Healthcare · Investment Strategies · NASDAQ:PRAX · Stock Market

Biggest Stock Gainers Today (December 5, 2025): TGL, SMX, WHLR, DBRG, TORO, PRAX and RBRK Lead a Volatile Session

The U.S. stock market logged another upbeat session on Friday, December 5, 2025, with the S&P 500, Nasdaq 100 and Dow all edging higher. But beneath the index-level moves, a cluster of highly volatile small caps, high‑growth tech names and

6 December 2025

Financial Analysis · Investing · Market News · NASDAQ:ALMS · NASDAQ:LICN · NASDAQ:PRAX · NASDAQ:SMX · NASDAQ:SPHL · NASDAQ:TDIC · NASDAQ:TGL · NASDAQ:TORO · NASDAQ:WAI · NASDAQ:WHLR · NYSE:DBRG · NYSE:RBRK · Stock Market · Trading

Praxis Precision Medicines (PRAX) Soars on FDA Momentum and Epilepsy Breakthroughs as Stock Hits New High on December 5, 2025

Praxis Precision Medicines, Inc. (NASDAQ: PRAX) extended its remarkable 2025 rally on Friday, December 5, with shares surging almost 40% intraday after the company reported a double dose of good news: a pivotal epilepsy trial stopped early for efficacy and

5 December 2025

Biotech Stocks · Epilepsy Research · FDA Approvals · Investment News · NASDAQ:PRAX · Pharmaceutical Industry

Praxis Precision Medicines (PRAX) Stock Surges on FDA Progress and Epilepsy Trial Wins: Latest News and 2026 Forecast

Updated December 5, 2025 – all developments since December 4, 2025 Praxis Precision Medicines, Inc. (NASDAQ: PRAX) has moved back into the market spotlight after a flurry of major announcements on December 4, 2025. The biotech’s stock — already one

5 December 2025

Biotech News · Epilepsy Research · FDA Updates · Investment Forecasts · NASDAQ:PRAX · Stock Market

Praxis (PRAX) Stock Skyrockets 180% on Game-Changing Tremor Drug Trial; Analysts See ‘Blockbuster’ Upside

PRAX Stock Soars on Historic Trial Win Praxis Precision Medicines stock has seen a record-breaking spike in recent days after announcing landmark clinical trial results. On October 16, PRAX shares closed at $162.71, up about 183% in a single session

17 October 2025

Biotechnology · Clinical Trials · Investment · NASDAQ:PRAX · Pharmaceuticals · Stocks

Praxis Precision (PRAX) Stock Skyrockets on Game-Changing Phase 3 Results – What Experts Say

Market Outlook With the stock now trading well above $150, investors are debating how much further PRAX could rise. If ulixacaltamide wins approval, analysts believe it could capture a sizable ET market. However, success in neurology trials can be binary

16 October 2025

Biotechnology · Financial Analysis · Investing · NASDAQ:PRAX · Pharma News · Stock Market

NASDAQ:PRAX News 16 October 2025 - 9 December 2025